{"id":24895,"date":"2022-06-21T13:56:54","date_gmt":"2022-06-21T11:56:54","guid":{"rendered":"https:\/\/ritme.com\/intel-oneapi-gromacs-2022\/"},"modified":"2022-06-23T10:30:28","modified_gmt":"2022-06-23T08:30:28","slug":"intel-oneapi-gromacs-2022","status":"publish","type":"post","link":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/","title":{"rendered":"GROMACS 2022 advances Open Source Drug Discovery with Intel oneAPI"},"content":{"rendered":"\n

GROMACS, accelerated by Intel oneAPI<\/mark><\/a> open programming and multiarchitecture tools, runs on Intel Xe architecture-based GPUs with strong performance. <\/strong><\/p>\n\n\n\n

Intel is committed to fostering an open ecosystem, including technical contributions to many open source projects that are making direct real-world impacts. One example is GROMACS<\/strong>, a molecular dynamics package designed for simulations of proteins, lipids and nucleic acids used to design new pharmaceuticals. Recently released GROMACS 2022, developed using SYCL and oneAPI<\/mark><\/a><\/strong>, exhibits strong performance running on multiple architectures, including Intel Xe architecture-based GPUs.<\/p>\n\n\n\n

<\/div>\n\n\n\n
<\/div>
\n

“GROMACS is one of the world\u2019s most widely used open source molecular dynamics applications, and it’s easy to see why. The simulations we can conduct with the application grants us better understanding into things as small as the proteins in our bodies to as large as the galaxies in the universe.<\/mark><\/strong><\/em>

Most notably, our work with GROMACS \u2013 developed and optimized with oneAPI \u2013 allows Intel to have a hand in significant advances in drug discovery and expands GROMACS open development across multiple compute architectures. And this is all while collaborating with the open source community that we so greatly value.\u201d<\/mark><\/strong><\/em><\/p>\n\n\n\n

<\/div>\n\n\n\n

– Roland Schulz<\/em><\/strong>, parallel software engineer at<\/em> Intel<\/strong><\/em><\/mark><\/p>\n<\/div><\/section>\n\n\n\n

<\/div>\n\n\n\n

Why It Matters<\/strong>?<\/mark><\/strong><\/h2>\n\n\n\n

GROMACS\u2019 molecular dynamic simulations, which are powered by oneAPI, contribute to the identification of crucial pharmaceutical solutions for conditions like breast cancer, COVID-19, Type 2 diabetes, and others. In modern drug discovery, molecular dynamic simulations are applied widely and successfully. These simulations provide researchers with the structural information on biomacromolecules needed to understand the structure-function relationship that guides the drug discovery and design process. The application of computational tools like GROMACS to drug discovery helps researchers more efficiently design and evaluate new drugs while conserving resources.<\/p>\n\n\n\n

The GROMACS research and development team at Stockholm University and KTH Royal Institute of Technology, directed by biophysics professor Erik Lindahl, leads the GROMACS molecular dynamics toolkit development, one of the world\u2019s most widely used HPC applications. Molecular dynamics is among the most time-consuming HPC applications because it is a very iterative, compute-focused problem. With computation happening billions of times, that means there are millions of lines of code involved.<\/p>\n\n\n\n

<\/div>\n\n\n\n

How It Works?<\/mark><\/strong><\/h2>\n\n\n\n

oneAPI, an open and unified programming model for CPUs and accelerators, supports multiple vendors\u2019 architectures, which helped Lindahl and his team expand GROMACS\u2019 support of heterogeneous hardware. This is due to improved productivity using cross-architecture and cross-vendor open standards. Based on these standards, oneAPI programming simplifies software development and delivers performance for accelerated computing without proprietary programming languages or vendor lock-in, while allowing integration of existing code, including OpenMP.<\/p>\n\n\n\n

As part of the oneAPI optimization work, Lindahl\u2019s team ported GROMACS\u2019 CUDA code, which only runs on Nvidia hardware, to SYCL using the Intel\u00ae DPC++ Compatibility Tool (part of the Intel\u00ae oneAPI Base Toolkit), which typically automates 90-95% of the code migration.1,2 This allowed the team to create a new, single portable codebase that is cross-architecture-ready, greatly streamlining development and providing flexibility for deployment in multiarchitecture environments.<\/p>\n\n\n\n

GROMACS accelerated compute was made possible through optimizations using Intel oneAPI cross-architecture tools, such as the oneAPI DPC++\/C++ Compiler, oneAPI libraries, and HPC analysis and cluster tools. The oneAPI tools are in the Intel\u00ae DevCloud, a free environment to develop and test code across a variety of Intel architectures (CPU, GPU, FPGA).<\/p>\n\n\n\n

<\/div>\n\n\n\n

Read the full article : GROMACS 2022 Advances open source drug discovery with One API<\/mark><\/a><\/p>\n\n\n\n

<\/div>\n\n\n\n

Source : Intel<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Learn how the latest version of GROMACS software, developed and optimized with Intel oneAPI, is enabling significant advances in the design of new pharmaceutical products.<\/p>\n","protected":false},"author":3370,"featured_media":24969,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[46],"tags":[],"class_list":["post-24895","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-labs-solutions"],"acf":[],"yoast_head":"\nSoftware Gromacs Intel oneAPI - Ritme<\/title>\n<meta name=\"description\" content=\"GROMACS software, developed and optimized with Intel oneAPI, enables advances in drug design of new pharmaceutical products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Software Gromacs Intel oneAPI - Ritme\" \/>\n<meta property=\"og:description\" content=\"GROMACS software, developed and optimized with Intel oneAPI, enables advances in drug design of new pharmaceutical products.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Ritme\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-21T11:56:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-23T08:30:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"674\" \/>\n\t<meta property=\"og:image:height\" content=\"476\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Olivier Ritme\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Olivier Ritme\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/\"},\"author\":{\"name\":\"Olivier Ritme\",\"@id\":\"https:\/\/ritme.com\/en\/#\/schema\/person\/602d787f042cd53a4689a969a54b4d96\"},\"headline\":\"GROMACS 2022 advances Open Source Drug Discovery with Intel oneAPI\",\"datePublished\":\"2022-06-21T11:56:54+00:00\",\"dateModified\":\"2022-06-23T08:30:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/\"},\"wordCount\":571,\"publisher\":{\"@id\":\"https:\/\/ritme.com\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png\",\"articleSection\":[\"Solutions\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/\",\"url\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/\",\"name\":\"Software Gromacs Intel oneAPI - Ritme\",\"isPartOf\":{\"@id\":\"https:\/\/ritme.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png\",\"datePublished\":\"2022-06-21T11:56:54+00:00\",\"dateModified\":\"2022-06-23T08:30:28+00:00\",\"description\":\"GROMACS software, developed and optimized with Intel oneAPI, enables advances in drug design of new pharmaceutical products.\",\"breadcrumb\":{\"@id\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#primaryimage\",\"url\":\"https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png\",\"contentUrl\":\"https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png\",\"width\":674,\"height\":476,\"caption\":\"Intel oneAPI - Gromacs 2022 (EN)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ritme.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Solutions\",\"item\":\"https:\/\/ritme.com\/en\/category\/labs-solutions-en\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"GROMACS 2022 advances Open Source Drug Discovery with Intel oneAPI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ritme.com\/en\/#website\",\"url\":\"https:\/\/ritme.com\/en\/\",\"name\":\"Ritme\",\"description\":\"The strategic partner of research teams\",\"publisher\":{\"@id\":\"https:\/\/ritme.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ritme.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ritme.com\/en\/#organization\",\"name\":\"RITME\",\"url\":\"https:\/\/ritme.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ritme.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ritme.com\/wp-content\/uploads\/2021\/06\/Ritme_200x86.svg\",\"contentUrl\":\"https:\/\/ritme.com\/wp-content\/uploads\/2021\/06\/Ritme_200x86.svg\",\"caption\":\"RITME\"},\"image\":{\"@id\":\"https:\/\/ritme.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ritme.com\/en\/#\/schema\/person\/602d787f042cd53a4689a969a54b4d96\",\"name\":\"Olivier Ritme\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ritme.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e766af435a9d437904f33762395f31273c9bfbb003cd5e2a6b1c2536fa1f594?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e766af435a9d437904f33762395f31273c9bfbb003cd5e2a6b1c2536fa1f594?s=96&d=mm&r=g\",\"caption\":\"Olivier Ritme\"},\"sameAs\":[\"http:\/\/adminRitme\"],\"url\":\"https:\/\/ritme.com\/en\/author\/olivier\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Software Gromacs Intel oneAPI - Ritme","description":"GROMACS software, developed and optimized with Intel oneAPI, enables advances in drug design of new pharmaceutical products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/","og_locale":"en_GB","og_type":"article","og_title":"Software Gromacs Intel oneAPI - Ritme","og_description":"GROMACS software, developed and optimized with Intel oneAPI, enables advances in drug design of new pharmaceutical products.","og_url":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/","og_site_name":"Ritme","article_published_time":"2022-06-21T11:56:54+00:00","article_modified_time":"2022-06-23T08:30:28+00:00","og_image":[{"width":674,"height":476,"url":"https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png","type":"image\/png"}],"author":"Olivier Ritme","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Olivier Ritme","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#article","isPartOf":{"@id":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/"},"author":{"name":"Olivier Ritme","@id":"https:\/\/ritme.com\/en\/#\/schema\/person\/602d787f042cd53a4689a969a54b4d96"},"headline":"GROMACS 2022 advances Open Source Drug Discovery with Intel oneAPI","datePublished":"2022-06-21T11:56:54+00:00","dateModified":"2022-06-23T08:30:28+00:00","mainEntityOfPage":{"@id":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/"},"wordCount":571,"publisher":{"@id":"https:\/\/ritme.com\/en\/#organization"},"image":{"@id":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png","articleSection":["Solutions"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/","url":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/","name":"Software Gromacs Intel oneAPI - Ritme","isPartOf":{"@id":"https:\/\/ritme.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#primaryimage"},"image":{"@id":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png","datePublished":"2022-06-21T11:56:54+00:00","dateModified":"2022-06-23T08:30:28+00:00","description":"GROMACS software, developed and optimized with Intel oneAPI, enables advances in drug design of new pharmaceutical products.","breadcrumb":{"@id":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#primaryimage","url":"https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png","contentUrl":"https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png","width":674,"height":476,"caption":"Intel oneAPI - Gromacs 2022 (EN)"},{"@type":"BreadcrumbList","@id":"https:\/\/ritme.com\/en\/intel-oneapi-gromacs-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ritme.com\/en\/"},{"@type":"ListItem","position":2,"name":"Solutions","item":"https:\/\/ritme.com\/en\/category\/labs-solutions-en\/"},{"@type":"ListItem","position":3,"name":"GROMACS 2022 advances Open Source Drug Discovery with Intel oneAPI"}]},{"@type":"WebSite","@id":"https:\/\/ritme.com\/en\/#website","url":"https:\/\/ritme.com\/en\/","name":"Ritme","description":"The strategic partner of research teams","publisher":{"@id":"https:\/\/ritme.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ritme.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ritme.com\/en\/#organization","name":"RITME","url":"https:\/\/ritme.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ritme.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ritme.com\/wp-content\/uploads\/2021\/06\/Ritme_200x86.svg","contentUrl":"https:\/\/ritme.com\/wp-content\/uploads\/2021\/06\/Ritme_200x86.svg","caption":"RITME"},"image":{"@id":"https:\/\/ritme.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ritme.com\/en\/#\/schema\/person\/602d787f042cd53a4689a969a54b4d96","name":"Olivier Ritme","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ritme.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e766af435a9d437904f33762395f31273c9bfbb003cd5e2a6b1c2536fa1f594?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e766af435a9d437904f33762395f31273c9bfbb003cd5e2a6b1c2536fa1f594?s=96&d=mm&r=g","caption":"Olivier Ritme"},"sameAs":["http:\/\/adminRitme"],"url":"https:\/\/ritme.com\/en\/author\/olivier\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png",674,476,false],"thumbnail":["https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1-300x300.png",300,300,true],"medium":["https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1-500x353.png",500,353,true],"medium_large":["https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png",674,476,false],"large":["https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png",674,476,false],"1536x1536":["https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png",674,476,false],"2048x2048":["https:\/\/ritme.com\/wp-content\/uploads\/2022\/06\/Intel-oneAPI-Gromacs-2022_Mise-en-Avant-EN-1.png",674,476,false]},"uagb_author_info":{"display_name":"Olivier Ritme","author_link":"https:\/\/ritme.com\/en\/author\/olivier\/"},"uagb_comment_info":0,"uagb_excerpt":"Learn how the latest version of GROMACS software, developed and optimized with Intel oneAPI, is enabling significant advances in the design of new pharmaceutical products.","_links":{"self":[{"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/posts\/24895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/users\/3370"}],"replies":[{"embeddable":true,"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/comments?post=24895"}],"version-history":[{"count":12,"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/posts\/24895\/revisions"}],"predecessor-version":[{"id":24981,"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/posts\/24895\/revisions\/24981"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/media\/24969"}],"wp:attachment":[{"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/media?parent=24895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/categories?post=24895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ritme.com\/en\/wp-json\/wp\/v2\/tags?post=24895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}